ZT-12-037-01, a Specific STK19 Inhibitor, Inhibits NRAS-driven Melanomagenesis
Activating mutations in NRAS account for 20%-30% of melanoma. but, there are no effective anti-NRAS therapies. Originally, it reports that the serine/threonine-protein kinase 19 (STK19) phosphorylate a-casein at serine/threonine residues…